Ciguatera Fish PoisoningMANAGEMENT

ENVIRONMENTAL AND EXPOSURE PRESENTATIONS · 12 SECTIONS

⚲

576 items

☷ Legend

⚲

Cardiovascular Presentations71▾

Respiratory Presentations52▾

Neurological Presentations83▾

Gastrointestinal Presentations74▾

Genitourinary and Reproductive Presentations48▾

Infectious Disease Presentations148▾

Trauma Presentations89▾

Toxicologic Presentations80▾

Psychiatric Presentations26▾

Musculoskeletal and Rheumatologic Presentations96▾

Dermatology Presentations23▾

Environmental and Exposure Presentations27▾

Acute Mountain Sickness Arterial Gas Embolism Bee-Wasp Sting (Anaphylaxis)Chilblains Ciguatera Fish Poisoning Coral Cut Decompression Sickness Electrical Burn Injury Envenomation (snake, spider, insect)High Altitude Cerebral Edema (HACE)High Altitude Pulmonary Edema (HAPE)High-altitude illness Hypothermia Hypothermia (Mild)Hypothermia (Severe)Immersion Foot Lightning Strike Injury Scombroid Fish Poisoning Scorpion Envenomation Sea Urchin Injury Shark Bite Snake Envenomation Spider Bite (Black Widow)Spider Bite (Brown Recluse)Stingray Spine Injury Tick paralysis White Phosphorus Burn

Hematologic and Oncologic Presentations36▾

Pediatric-Specific Presentations19▾

Endocrine and Metabolic Presentations45▾

ENT and Maxillofacial Presentations27▾

Ophthalmologic Presentations19▾

Obstetric Presentations23▾

Systemic and Miscellaneous Presentations17▾

01Approach to the Critical Patient/attcp45

Immediate stabilization

›Airway and hemodynamic threats

›Cardiovascular compromise

›Symptomatic bradycardia with hemodynamic instability

›Heart block on ECG

›Hypotension unresponsive to initial IV fluids

›Altered mental status

›Rare but reported with severe toxin load

›Exclude hypoglycemia and alternative CNS pathology

›Severe dehydration from profuse vomiting and diarrhea

›IV crystalloid bolus 20–30 ml/kg for volume repletion

›Reassess hemodynamics after initial resuscitation

›If symptomatic bradycardia, atropine 0.5–1 mg IV immediately

›May repeat to maximum 3 mg total

›Transcutaneous pacing standby if refractory

Monitoring and targets

›Monitoring bundle

›Continuous cardiac monitoring for bradycardia and conduction abnormalities

›ECG for heart block identification

›Rate and rhythm trend every 15–30 minutes

›Pulse oximetry

›SpO2 target >= 94%

›Supplemental oxygen if respiratory symptoms present

›Electrolyte and fluid monitoring

›Serial BMP for electrolyte losses from GI symptoms

›Urine output target >= 0.5 ml/kg/hr

›Escalation triggers

›Persistent bradycardia after atropine

02History/hx61

Exposure and ingestion history

›Fish identification details

›Species consumed

›High-risk species: barracuda, grouper, amberjack, moray eel, snapper, sea bass

›Large carnivorous reef fish carrying higher toxin loads

›Fish size

›Fish weighing >2.3 kg (5 lbs) associated with higher toxin concentration

›Fish parts consumed

›Head, liver, intestines, and roe concentrate ciguatoxin

›Geographic origin

›Tropical and subtropical waters between 35 degrees N and 35 degrees S latitude

›Caribbean, Pacific, and Indian Ocean endemic regions

›Imported fish in non-endemic areas as emerging risk

Symptom timeline and characterization

›Onset timing

›GI symptoms typically within 3–6 hours of ingestion

›Neurologic symptoms follow over next 24 hours

›Symptom onset can be delayed up to 30 hours

›Gastrointestinal symptoms

›Nausea and vomiting

›Diarrhea and abdominal cramping

›Typically self-limited within 24–48 hours

›Neurologic symptoms

›Paresthesias: perioral, hands, and feet

›Cold allodynia: burning dysesthesia when touching cold objects

›Metallic taste

›Loose-tooth sensation or dental pain

›Pruritus: generalized

03Physical Exam/exam51

Vital signs and general

›Hemodynamic stability assessment

›Heart rate

›Bradycardia as primary cardiovascular finding

›Rate and rhythm irregularity for heart block detection

›Blood pressure

›Orthostatic hypotension common

›Frank hypotension in severe cases

›Temperature

›Normal in CFP; fever suggests bacterial co-infection or alternative diagnosis

›Respiratory rate

›Respiratory distress rare; presence suggests high toxin load or alternative diagnosis

›General appearance

›Distress from GI symptoms and neurologic discomfort

›Signs of dehydration: dry mucosa, decreased skin turgor

Neurologic examination

›Sensory exam

›Cold allodynia provocation test: apply ice or cold object to skin

›Burning dysesthesia is nearly pathognomonic

›Pin-prick and light touch in glove-and-stocking distribution

›Vibration sense testing

›Reflexes

›Deep tendon reflexes: areflexia in approximately 10% of cases

›Cerebellar signs

›Ataxia: finger-nose and heel-shin testing

›Gait assessment

›Mental status

›Confusion and altered sensorium in severe toxin load

04Differential Diagnosis/ddx46

Life-threatening alternatives

›Cardiac conduction emergencies

›Primary dysrhythmia or heart block unrelated to toxin

›ECG differentiation required

›No fish ingestion history

›Organophosphate poisoning

›Cholinergic toxidrome: SLUDGE syndrome

›Different exposure history

›Neurotoxic emergencies

›Tetrodotoxin poisoning (pufferfish)

›Rapid ascending paralysis and respiratory failure

›Pufferfish ingestion history

›ICD-10 T61.771A

›Paralytic shellfish poisoning

›Shellfish ingestion

›Rapid-onset paresthesias and paralysis

›Respiratory failure in severe cases

›Botulism

›Descending paralysis with cranial nerve involvement

›No sensory symptoms

›No GI prodrome to neurologic progression

Common mimics

›Scombroid fish poisoning

›Histamine-mediated after spoiled tuna, mahi-mahi, mackerel

›Flushing, urticaria, and rapid onset within 1 hour

›Responds to antihistamines

›No cold allodynia

›ICD-10 T61.11XA

05Laboratory Tests/lt34

Core metabolic labs

›Basic metabolic panel

›Sodium, potassium, and chloride for GI loss assessment

›Hypokalemia from vomiting and diarrhea

›Hyponatremia with severe fluid losses

›Renal function

›Creatinine and BUN for toxin clearance assessment

›Medication dosing adjustment inputs

›Glucose

›Hypoglycemia exclusion in altered mental status

›Complete blood count

›Leukocytosis suggesting infectious or bacterial etiology

›Normal white cell count supporting CFP over bacterial gastroenteritis

›Hepatic panel

›Baseline for medication metabolism consideration

›Hepatic disease may impair toxin clearance

Cardiac and perfusion labs

›Troponin

›Elevated in significant bradycardia or cardiovascular symptoms

›Myocardial injury screening

›Lactate

›>= 2 mmol/l as organ hypoperfusion marker

›Obtain if hemodynamically unstable

›ECG — mandatory in all patients with suspected CFP

›Bradycardia pattern identification

›Heart block degree classification: first, second, third degree

›QTc prolongation monitoring

06Diagnostic Tests/dt49

Scoring Systems

›Severity stratification approach

›No validated clinical scoring system specific to CFP

›Severity classified as mild, moderate, or severe based on clinical features

›Mild: GI symptoms with mild paresthesias, hemodynamically stable

›Moderate: Prominent neurologic symptoms, mild bradycardia, orthostatic hypotension

›Severe: Significant bradycardia or heart block, hypotension, coma

›Chronic symptom burden assessment

›Neurologic symptoms persist in approximately 40% at 2 weeks

›Symptoms can last months to years in chronic CFP

›Psychiatric symptom burden tracked at follow-up visits

MRI

›Brain MRI indications

›Atypical neurologic findings warranting alternative diagnosis exclusion

›Focal motor deficits not explained by CFP

›Persistent altered mental status

›Stroke exclusion

›Chronic neuropathy workup

›Spinal cord pathology exclusion in chronic cases

›Nerve conduction studies and EMG

›Characterize polyneuropathy in chronic cases with persistent symptoms

›Differentiate from Guillain-Barre syndrome when motor symptoms predominate

›MRI limitations in CFP

›Not indicated for routine acute CFP

›Brain MRI typically normal in CFP

›Reserve for atypical presentations only

›CT indications in CFP

07Disposition/dispo34

Admission indications

›Inpatient admission criteria

›Cardiovascular instability

›Significant bradycardia or heart block

›Hypotension unresponsive to initial fluid resuscitation

›Severe dehydration

›Unresponsive to initial IV fluid bolus

›Inability to tolerate oral fluids

›Altered mental status or coma

›Severe neurologic symptoms

›Ataxia with fall risk

›Significant motor weakness

›ICU level care for vasopressor requirement or transcutaneous pacing

Observation indications

›Observation criteria

›Moderate bradycardia responding to atropine

›Monitoring for 6–12 hours

›Ongoing GI losses requiring IV hydration

›Monitoring after mannitol administration

›Uncertainty about clinical trajectory in moderate severity

Discharge criteria

›Safe discharge criteria

›Hemodynamically stable with normal heart rate

›No bradycardia or conduction abnormalities on repeat ECG

›Tolerating oral fluids without vomiting

›Mild-to-moderate neurologic symptoms without cardiovascular compromise

›Paresthesias and pruritus manageable with outpatient medications

›Reliable follow-up plan and understanding of return precautions

08Treatment/t76

Initial resuscitation

›IV access and hydration

›IV crystalloid for dehydration and hypotension

›Normal saline or lactated Ringer bolus 20–30 ml/kg

›Reassess hemodynamics after each fluid bolus

›Electrolyte repletion

›IV potassium replacement for hypokalemia from GI losses

›Oral rehydration when tolerated

Cardiac interventions

›Bradycardia management

›Atropine IV for symptomatic bradycardia

›0.5–1 mg IV bolus

›May repeat every 3–5 minutes

›Maximum total dose 3 mg

›Transcutaneous pacing for refractory bradycardia

›Standby if atropine insufficient

›Transvenous pacing for sustained high-degree heart block

›Vasopressor for refractory hypotension

›Phenylephrine (alpha-adrenergic agonist preferred)

›100–200 mcg IV bolus for acute hypotension

›Infusion 0.5–5 mcg/kg/min titrated to MAP >= 65 mmHg

›Avoid epinephrine and beta-agonists if possible

›May worsen tachyarrhythmia in CFP context

Antiemetic therapy

›Nausea and vomiting management

›Ondansetron IV for acute vomiting

›4 mg IV every 6 hours as needed

›8 mg IV for severe vomiting

›Metoclopramide 10 mg IV as alternative

›Avoid in patients with movement disorder history

›NPO if actively vomiting until nausea controlled

Decontamination

›Activated charcoal

›50 g PO if within 1–2 hours of ingestion and patient not vomiting

›Adsorbs unabsorbed ciguatoxin in GI tract

›Do not administer if vomiting or airway not protected

›Gastric lavage rarely indicated

Mannitol therapy

›IV mannitol — controversial

›Historical use supported by case reports and small series

›Palafox et al. 1988 JAMA: case series showing benefit

›Randomized controlled trial evidence

›Schnorf et al. 2002 Neurology: double-blind RCT showed no benefit over normal saline

›Mullins and Hoffman 2017 Clinical Toxicology: no benefit confirmed

›Current recommendation: consider in select acute cases

›Within 48 hours of symptom onset

›Significant neurologic symptoms

›Hemodynamically stable and well hydrated

›Dosing if used

›1 g/kg IV over 30–45 minutes

›Monitor blood pressure during infusion

›Contraindicated in hemodynamically unstable or dehydrated patients

›Evidence level: ACEP Level C recommendation

Pruritus management

›Antihistamines for pruritus

›Diphenhydramine 25–50 mg PO or IV every 6 hours as needed

›Hydroxyzine 25–50 mg PO every 6–8 hours as needed

›Cetirizine 10 mg PO daily for less sedating option

Chronic and neuropathic symptom management

›Neuropathic pain and paresthesias

›Gabapentin

›300 mg PO TID initial dose

›Titrate to 600 mg TID as tolerated

›Renal dose adjustment required for impaired clearance

›Pregabalin as alternative

›75 mg PO BID initial dose

›Titrate to 150 mg PO BID

›Chronic paresthesias and depression

›Amitriptyline

›25–75 mg PO at bedtime

›Anticholinergic side effects monitoring

›QTc prolongation monitoring

›Chronic fatigue

›Fluoxetine 20 mg PO daily

›Titrate after 4 weeks if inadequate response

›Headache management

›Acetaminophen 500–1000 mg PO every 6 hours as needed

›Nifedipine for refractory headache: 10 mg PO TID

Avoidance and contraindications

›Medications to avoid or use cautiously

›Opioids: may worsen hypotension and bradycardia

›Calcium channel blockers: may worsen bradycardia and conduction defects

›Beta-blockers: compound bradycardia

›Mannitol contraindicated in dehydration or hemodynamic instability

09Special Populations/sp58

Pregnancy

›CFP in pregnancy

›Risk to fetus from ciguatoxin

›Ciguatoxin crosses placenta; fetal exposure possible

›Reports of fetal bradycardia and distress

›Fetal monitoring when viable gestation if maternal bradycardia or hypotension

›Maternal hemodynamic priority

›IV fluid resuscitation as in non-pregnant adults

›Left lateral positioning for supine hypotension syndrome

›Atropine for symptomatic bradycardia: same dosing, monitor fetal heart rate

›Medication safety in pregnancy

›Ondansetron: generally considered acceptable for acute nausea

›Diphenhydramine: Category B, acceptable for pruritus

›Mannitol: avoid if possible; may reduce placental perfusion

›Amitriptyline: Category C, use cautiously for chronic symptoms

›Gabapentin: limited human data, use with caution

›Fluoxetine: Category C, neonatal adaptation syndrome risk

›Breastfeeding

›Ciguatoxin reported in breast milk; temporary cessation recommended

›Restart breastfeeding once clinically recovered

›Imaging

›CXR with abdominal shielding if respiratory symptoms require imaging

›CT only when benefits outweigh radiation risk

Geriatric

›Older adult considerations

›Atypical presentation

›Cold allodynia may be less reliably elicited in pre-existing neuropathy

›Dehydration decompensates faster with less reserve

10Background/b65

Epidemiology

›Global burden

›Most common nonbacterial seafood-borne illness worldwide

›Estimated 10,000–50,000 cases annually globally

›Significant underreporting due to clinical diagnosis and mild cases

›Geographic distribution

›Endemic to tropical and subtropical marine regions between 35 degrees N and 35 degrees S latitude

›Caribbean, Pacific Islands, and Indian Ocean highest burden

›Increasing reports in non-endemic regions from imported fish

›Mortality

›Less than 0.1% case fatality rate

›Higher mortality in resource-limited settings with poor access to supportive care

›Chronic course

›Neurologic symptoms persist in approximately 40% of patients at 2 weeks

›Symptoms can persist months to years in chronic CFP

›Risk factors for acquisition

›Consumption of large carnivorous reef fish over 2.3 kg

›Eating high-risk fish parts: head, liver, intestines, roe

›Coral reef degradation increasing Gambierdiscus toxicus blooms

›Prior CFP episode increasing sensitization risk

Pathophysiology

›Toxin source and bioaccumulation

›Ciguatoxin produced by dinoflagellate Gambierdiscus toxicus

›G. toxicus adheres to coral reef algae

›Small reef fish ingest the algae

›Toxin bioaccumulates up the food chain to large carnivorous predator fish

›Toxin characteristics

›Heat stable: not destroyed by cooking

11Patient Discharge Instructions/pdi35

copy discharge instructions

›What happened

›Ciguatera fish poisoning from eating contaminated reef fish

›The fish contained a natural toxin called ciguatoxin

›The toxin causes nerve symptoms and stomach symptoms

›There is no antidote; treatment is supportive

›Medications prescribed

›Antihistamine for itching as directed

›Anti-nausea medication as needed

›Nerve pain medication if prescribed: take as directed and do not stop suddenly

›Critical dietary restrictions — must follow for at least 6 months

›Avoid all fish and seafood

›Avoid alcohol

›Avoid caffeine (coffee, tea, energy drinks)

›Avoid nuts

›These can cause your symptoms to return even after recovery

›Long-term fish avoidance advice

›Permanently avoid barracuda and moray eel

›Avoid large reef fish over 2.3 kg (5 lbs)

›Avoid fish head, liver, intestines, and roe permanently

›What to expect

›Nerve symptoms (tingling, burning on cold touch, itching) may last weeks to months

›Fatigue and mood changes are expected parts of recovery

›Symptoms may fluctuate and worsen transiently — this is common

›Warning signs to return to ER immediately

›Worsening weakness or difficulty walking

›Chest pain, palpitations, fainting, or near-fainting

›Inability to keep fluids down

12References/r22

Guidelines and key sources

›Primary evidence sources

›Ansdell VE. Food Poisoning from Marine Toxins. CDC Yellow Book 2025

›Comprehensive clinical review of ciguatera diagnosis and management

›Isbister GK, Kiernan MC. Neurotoxic Marine Poisoning. Lancet Neurology 2005

›Neurological mechanisms and differential diagnosis

›Patel M, Jutzy K. A Curious Case of Ciguatera Fish Poisoning in the Midwest. J Emerg Med 2020

›Clinical case review and emergency physician reference

›Key trials

›Schnorf H, Taurarii M, Cundy T. Ciguatera Fish Poisoning: A Double-Blind Randomized Trial of Mannitol Therapy. Neurology 2002

›Only RCT on mannitol: no benefit over normal saline

›Palafox NA et al. Successful Treatment of Ciguatera Fish Poisoning With Intravenous Mannitol. JAMA 1988

›Historical case series supporting mannitol use

›Mullins ME, Hoffman RS. Is Mannitol the Treatment of Choice for Patients With Ciguatera Fish Poisoning? Clin Toxicol 2017

›Systematic review confirming no benefit of mannitol

›Surveillance and epidemiology

›Ciguatera Fish Poisoning — Texas and South Carolina. MMWR 2006

›Cluster of Ciguatera Fish Poisoning — North Carolina 2007. MMWR 2009

›Chan TY. Epidemiology and Clinical Features of Ciguatera Fish Poisoning in Hong Kong. Toxins 2014

›Résière D et al. Clinical Characteristics of Ciguatera Poisoning in Martinique. Toxins 2022

›Coding references

›ICD-10 T61.01XA ciguatera fish poisoning initial encounter

›SNOMED CT ciguatera poisoning disorder

Learn More: Ciguatera Fish Poisoning→

Comprehensive Clinical Review

Structured, evidence-informed, long-form analysis for deeper understanding.

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed August 18, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.